• Nuance Pharma successfully launched Bentrio® nasal spray for protection against airborne particles in Hong Kong and filed request for marketing authorization for Mainland China 
• Extension of Exclusive License and Distribution Agreement to include seven additional countries across East and South East Asia with cumulated population > 630 million 

Nuance Pharma (the "Company") announced that it has agreed with Altamira Medica Ltd., an associate company of Altamira Therapeutics Ltd. (Nasdaq:CYTO), to extend the territory covered by the exclusive license and distribution agreement for Bentrio® nasal spray by several countries across South East and East Asia. Under the amended agreement, Nuance's territory will expand from China (Mainland, Hong Kong, Macau) and South Korea to also include Singapore, Malaysia, Thailand, Philippines, Indonesia, Vietnam and Taiwan, with a combined population of greater than 630 million people. Nuance has been marketing Bentrio in Hong Kong since late 2022 and recently submitted the request for marketing approval for Mainland China.

"We are excited to reinforce and expand our successful collaboration with Altamira on Bentrio," stated Mark Lotter, founder and CEO of Nuance Pharma. "Bentrio offers some unique features such as immediate onset and long duration of protection against airborne particles, strong efficacy and good tolerability thanks to its drug-free and preservative-free formulation. They resonate well with medical professionals and consumers, and we look forward to rolling out the product in additional countries and marketing it through our large sales force and growing network of partners."

"We are very satisfied with the collaboration with our partner Nuance who has shown great dedication and launched Bentrio successfully in Hong Kong," commented Thomas Meyer, Altamira Medica's Chairman and CEO. "Together with Nuance we look forward to making Bentrio available in further countries, first in the existing license territory and subsequently also in the newly added countries to provide relief to the growing number of allergic rhinitis patients in East and South East Asia."